Browse drugs

…s received BLM after bDMARD. The main bDMARD use before BLM was rituximab in the 85.3% of patients. Baseline characteristics are summariz…

…CR 2019, SLICC and/or ACR 1997 diagnostic criteria treated with Belimumab in monotherapy. Data were collected from medical records of SLE…

…11), antimalarials (n= 55), tacrolimus (n= 27), everolimus (1), belimumab (BLM) (19) and anifrolumab (1). After a follow-up of 59.7±46 mo…

…ed expression of Cyp1a1, a marker of AhR signalling.Conclusions Ficz, an AhR agonist, can alleviate skin fibrosis in BLM-induced SSc…